Georgia § 31-15a-2 Definitions

Georgia Statutes

§ 31-15a-2 — Definitions

Georgia § 31-15a-2

Title31

This text of Georgia § 31-15a-2 (Definitions) is published on Counsel Stack Legal Research, covering Georgia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

O.C.G.A. § 31-15a-2 (2026).

Text

As used in this chapter, the term:

(1)"Accident and sickness insurance benefit plan, policy, or contract" has the meaning provided by paragraph (1) of subsection (a) of Code Section 33-24-28.1 , provided that such term shall not include a limited benefit insurance policy as defined in paragraph (4) of subsection (f) of Code Section 33-30-12 .

(2)"Bone mass measurement" means a radiologic or radioisotopic procedure or other technologies approved by the United States Food and Drug Administration and performed on an individual for the purpose of identifying bone mass or detecting bone loss.

(3)"Qualified individual" means an:

(A)Estrogen-deficient woman or individual at clinical risk of osteoporosis as determined directly or indirectly by a physician and who is considering treatment;

(B)

Free access — add to your briefcase to read the full text and ask questions with AI

As used in this chapter, the term: (1) "Accident and sickness insurance benefit plan, policy, or contract" has the meaning provided by paragraph (1) of subsection (a) of Code Section 33-24-28.1 , provided that such term shall not include a limited benefit insurance policy as defined in paragraph (4) of subsection (f) of Code Section 33-30-12 . (2) "Bone mass measurement" means a radiologic or radioisotopic procedure or other technologies approved by the United States Food and Drug Administration and performed on an individual for the purpose of identifying bone mass or detecting bone loss. (3) "Qualified individual" means an: (A) Estrogen-deficient woman or individual at clinical risk of osteoporosis as determined directly or indirectly by a physician and who is considering treatment; (B) Individual with osteoporotic vertebral abnormalities; (C) Individual receiving long-term glucocorticoid (steroid) therapy; (D) Individual with primary hyperparathyroidism; or (E) Individual being monitored directly or indirectly by a physician to assess the response to or efficacy of approved osteoporosis drug therapies.